In discussing the issue of inflammatory bowel disease (IBD) in patients receiving IL-17 blockers, the experts acknowledge the cautionary language in package inserts based on early studies. While there was initial concern about potential exacerbation of IBD with IL-17 blockers, subsequent real-world data have not shown increased or worsened IBD symptoms. Their approach to managing patients with a history of or suspected IBD involves thorough screening, including personal and family history, and symptoms such as bloody stools or nocturnal bowel movements. They also highlight the importance of distinguishing between irritable bowel syndrome (IBS) and IBD, as patients may confuse the two.

Despite the low prevalence of IBD in psoriasis patients and the relatively rare occurrence of IBD exacerbation with IL-17 blockers, the dermatologists exercise caution, particularly in patients with a confirmed diagnosis of IBD. They may avoid prescribing IL-17 blockers in such cases or closely monitor patients with a family history of Crohn's disease. While acknowledging the rarity of IBD exacerbation with IL-17 blockers, the experts prioritize patient safety and consider alternative biologic options for individuals with a history of or increased risk for IBD, including TNF blockers or other targeted therapies. Their approach reflects a balanced assessment of available evidence and individual patient factors to optimize treatment outcomes while minimizing potential risks.

Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.